News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK)-Pfizer Inc. (PFE) AIDS Pill May Dislodge Bristol-Myers Squibb Company (BMY)'s, Study Suggests


7/19/2011 7:37:06 AM

A drug developed by GlaxoSmithKline Plc (GSK) and Pfizer Inc. (PFE) controlled HIV faster and more safely than Bristol-Myers Squibb Co. (BMY)’s Sustiva in a study, suggesting the experimental medicine may one day be preferred to Bristol’s. Dolutegravir, a product of Glaxo and Pfizer’s ViiV Healthcare joint venture, reduced HIV to undetectable levels in 90 percent of patients after 48 weeks, compared with 82 percent of those who got Sustiva, according to results presented at an AIDS meeting in Rome today. Dolutegravir also caused a significantly lower rise in bad cholesterol than Sustiva, at one-twelfth of the dose size.

Read at Bloomberg

comments powered by Disqus
Bloomberg
   
HIV/AIDS

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES